Jagpreet Chhatwal1,2,3, Sumeyye Samur1,2, Emily D Bethea1,2,3, Turgay Ayer4, Fasiha Kanwal5,6, Chin Hur1,2,3, Mark S Roberts7,8, Norah Terrault9, Raymond T Chung2,3. 1. Massachusetts General Hospital Institute for Technology Assessment, Boston, MA. 2. Harvard Medical School, Boston, MA. 3. Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA. 4. Department of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA. 5. Department of Medicine, Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX. 6. Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX. 7. Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA. 8. University of Pittsburgh School of Medicine, Pittsburgh, PA. 9. University of California San Francisco Medical Center, San Francisco, CA.
Abstract
Under current guidelines, hepatitis C virus (HCV)-positive livers are not transplanted into HCV-negative recipients because of adverse posttransplant outcomes associated with allograft HCV infection. However, HCV can now be cured post-LT (liver transplant) using direct-acting antivirals (DAAs) with >90% success; therefore, HCV-negative patients on the LT waiting list may benefit from accepting HCV-positive organs with preemptive treatment. Our objective was to evaluate whether and in which HCV-negative patients the potential benefit of accepting an HCV-positive (i.e., viremic) organ outweighed the risks associated with HCV allograft infection. We developed a Markov-based mathematical model that simulated a virtual trial of HCV-negative patients on the LT waiting list to compare long-term outcomes in patients: (1) willing to accept any (HCV-negative or HCV-positive) liver versus (2) those willing to accept only HCV-negative livers. Patients receiving HCV-positive livers were treated preemptively with 12 weeks of DAA therapy and had a higher risk of graft failure than those receiving HCV-negative livers. The model incorporated data from published studies and the United Network for Organ Sharing (UNOS). We found that accepting any liver regardless of HCV status versus accepting only HCV-negative livers resulted in an increase in life expectancy when Model for End-Stage Liver Disease (MELD) was ≥20, and the benefit was highest at MELD 28 (0.172 additional life-years). The magnitude of clinical benefit was greater in UNOS regions with higher HCV-positive donor organ rates, that is, Regions 1, 2, 3, 10, and 11. Sensitivity analysis demonstrated that model outcomes were robust. CONCLUSION: Transplanting HCV-positive livers into HCV-negative patients with preemptive DAA therapy could improve patient survival on the LT waiting list. Our analysis can help inform clinical trials and minimize patient harm. (Hepatology 2018;67:2085-2095).
Under current guidelines, hepatitis C virus (HCV)-positive livers are not transplanted into HCV-negative recipients because of adverse posttransplant outcomes associated with allograft HCV infection. However, HCV can now be cured post-LT (liver transplant) using direct-acting antivirals (DAAs) with >90% success; therefore, HCV-negative patients on the LT waiting list may benefit from accepting HCV-positive organs with preemptive treatment. Our objective was to evaluate whether and in which HCV-negative patients the potential benefit of accepting an HCV-positive (i.e., viremic) organ outweighed the risks associated with HCV allograft infection. We developed a Markov-based mathematical model that simulated a virtual trial of HCV-negative patients on the LT waiting list to compare long-term outcomes in patients: (1) willing to accept any (HCV-negative or HCV-positive) liver versus (2) those willing to accept only HCV-negative livers. Patients receiving HCV-positive livers were treated preemptively with 12 weeks of DAA therapy and had a higher risk of graft failure than those receiving HCV-negative livers. The model incorporated data from published studies and the United Network for Organ Sharing (UNOS). We found that accepting any liver regardless of HCV status versus accepting only HCV-negative livers resulted in an increase in life expectancy when Model for End-Stage Liver Disease (MELD) was ≥20, and the benefit was highest at MELD 28 (0.172 additional life-years). The magnitude of clinical benefit was greater in UNOS regions with higher HCV-positive donor organ rates, that is, Regions 1, 2, 3, 10, and 11. Sensitivity analysis demonstrated that model outcomes were robust. CONCLUSION: Transplanting HCV-positive livers into HCV-negative patients with preemptive DAA therapy could improve patient survival on the LT waiting list. Our analysis can help inform clinical trials and minimize patient harm. (Hepatology 2018;67:2085-2095).
Authors: Douglas E Schaubel; Dawn M Dykstra; Susan Murray; Valarie B Ashby; Keith P McCullough; David M Dickinson; Tempie E Hulbert-Shearon; Randall L Webb; Robert A Wolfe Journal: Am J Transplant Date: 2005-04 Impact factor: 8.086
Authors: Steven M Shechter; Cindy L Bryce; Oguzhan Alagoz; Jennifer E Kreke; James E Stahl; Andrew J Schaefer; Derek C Angus; Mark S Roberts Journal: Med Decis Making Date: 2005 Mar-Apr Impact factor: 2.583
Authors: Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns Journal: Lancet Infect Dis Date: 2016-02-18 Impact factor: 25.071
Authors: Jagpreet Chhatwal; Sumeyye Samur; Brian Kues; Turgay Ayer; Mark S Roberts; Fasiha Kanwal; Chin Hur; Drew Michael S Donnell; Raymond T Chung Journal: Hepatology Date: 2017-01-06 Impact factor: 17.425
Authors: U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong Journal: Gut Date: 2003-03 Impact factor: 23.059
Authors: W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske Journal: Am J Transplant Date: 2017-01 Impact factor: 8.086
Authors: Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed Journal: Gastroenterology Date: 2014-11-25 Impact factor: 22.682
Authors: Marina Berenguer; Martín Prieto; Fernando San Juan; José M Rayón; Fernando Martinez; Domingo Carrasco; Angel Moya; Francisco Orbis; José Mir; Joaquín Berenguer Journal: Hepatology Date: 2002-07 Impact factor: 17.425
Authors: George Cholankeril; Andrew A Li; Brittany B Dennis; Alice E Toll; Donghee Kim; C Andrew Bonham; Satheesh Nair; Aijaz Ahmed Journal: Clin Gastroenterol Hepatol Date: 2018-09-27 Impact factor: 11.382
Authors: Alberto Ferrarese; Giacomo Germani; Martina Gambato; Francesco Paolo Russo; Marco Senzolo; Alberto Zanetto; Sarah Shalaby; Umberto Cillo; Giacomo Zanus; Paolo Angeli; Patrizia Burra Journal: World J Gastroenterol Date: 2018-10-14 Impact factor: 5.742